In short: Both psilocybin and stimulant medications like Adderall and Vyvanse increase heart rate and blood pressure through overlapping physiological pathways. Stacking them multiplies cardiovascular load, and adding an MAOI creates a triple interaction documented in a published case report of hypertensive emergency. This article explains the mechanisms, the evidence, and what people taking stimulants need to know before considering microdosing.
The psilocybin and Adderall interaction is not theoretical — a 2024 case report in the Journal of Psychoactive Drugs documented a hypertensive emergency in a patient who combined psilocybin, dextroamphetamine-amphetamine (Adderall), and the MAOI tranylcypromine. That single case crystallises a broader pharmacological problem: both stimulant medications and psilocybin independently push cardiovascular parameters upward, and combining them compounds that load in ways that are hard to predict and potentially dangerous.
This article is a cluster piece in our Microdosing Safety pillar. It focuses specifically on ADHD stimulants — amphetamine salts (Adderall, Vyvanse) and methylphenidate (Ritalin, Concerta) — and what happens when they share the body with psilocybin or psilocin.
How psilocybin affects the cardiovascular system
Psilocybin is converted rapidly to psilocin after ingestion. Psilocin acts primarily as a 5-HT2A receptor agonist, but also binds to 5-HT2B receptors and a range of adrenergic receptors. The cardiovascular consequences are measurable and transient.
A pooled analysis of 14 clinical studies (536 sessions, Johns Hopkins, published as a medRxiv preprint in 2026) found that psilocybin produces dose-dependent, transient increases in both systolic blood pressure and heart rate. Mean peak systolic blood pressure rose approximately 8–15 mmHg above baseline across moderate and high dose conditions, with heart rate rising 5–10 bpm. Effects were most pronounced in the first two hours and resolved as the drug cleared. The authors note these are "clinically meaningful" changes in people with pre-existing cardiovascular vulnerability (Johns Hopkins pooled analysis, medRxiv 2026).
The UCSF Translational Psychedelic Research program lists cardiovascular disease as one of the primary physical contraindications to classic psychedelic use, specifically citing transient blood pressure elevation and the absence of safety data in people with active cardiac conditions (UCSF Medical Contraindications). See also our companion piece on psilocybin and blood pressure medication interactions for the broader cardiovascular picture.
How stimulant medications affect the cardiovascular system
Amphetamine-based medications (Adderall, Vyvanse) and methylphenidate (Ritalin) are sympathomimetics: they increase the release and inhibit the reuptake of norepinephrine and dopamine in the central and peripheral nervous systems. The peripheral effect is direct cardiovascular stimulation.
At therapeutic doses, stimulant medications typically raise resting systolic blood pressure by 5–10 mmHg and increase resting heart rate by 3–7 bpm on average. These are considered acceptable in healthy individuals under clinical supervision, but the figures are additive with any co-administered substance that independently raises the same parameters.
Sarparast et al., writing in Psychiatric Times in a clinician-oriented pharmacological interactions guide, specifically flag stimulant co-administration as a category of concern with psilocybin, noting that the overlap in sympathomimetic activity and serotonergic modulation creates a pharmacodynamic interaction that is poorly characterised but mechanistically plausible (Sarparast et al., Psychiatric Times).
The stacking problem: when both drugs act at once
Cardiovascular stacking occurs when two or more agents simultaneously drive the same physiological direction — in this case, increased sympathetic tone, elevated blood pressure, and raised heart rate. Neither agent alone may produce dangerous levels; together, their effects can be additive or supra-additive.
For someone taking a stable therapeutic dose of Adderall who then takes a microdose or moderate dose of psilocybin, the combined cardiovascular demand may still stay within tolerable limits for a young healthy adult — but there is no clinical data establishing safe parameters, and individual variation is substantial. Heart rate and blood pressure responses to psilocybin vary widely between individuals even in controlled settings (Johns Hopkins pooled analysis, 2026). For someone with hypertension, a structural cardiac abnormality, or reduced cardiac reserve, the combined burden may tip into territory where risk is genuine.
The MAOI escalation: a documented case
The risk escalates sharply when an MAOI is added to the combination. Monoamine oxidase inhibitors, which include tranylcypromine and phenelzine (prescribed for treatment-resistant depression) and, importantly, Syrian rue (Peganum harmala) used in some psychedelic preparations, inhibit the enzymatic breakdown of monoamines including norepinephrine and dopamine.
When an MAOI is present alongside a stimulant medication, catecholamine clearance is impaired, and the sympathomimetic effects of the stimulant are dramatically amplified — a mechanism that underlies the well-documented and dangerous MAOI–stimulant interaction already carried as a black-box warning in stimulant prescribing information. Adding psilocybin to this already-dangerous pairing creates a three-way interaction with compounding cardiovascular effects.
The 2024 case report in the Journal of Psychoactive Drugs documents exactly this scenario: a patient taking dextroamphetamine-amphetamine (Adderall) and the MAOI tranylcypromine developed a hypertensive emergency after taking psilocybin. The authors present this as a cautionary illustration of cardiovascular stacking and call for explicit contraindication guidance in clinical and harm-reduction contexts (Hypertensive Emergency Secondary to Combining Psilocybin, Dextroamphetamine-Amphetamine, and Tranylcypromine, J Psychoactive Drugs, 2024).
For more on psilocybin and MAOI interactions beyond the cardiovascular domain, see our related guide on psilocybin serotonin supplement interactions, and our acute cardiovascular effects explainer at psilocybin acute cardiovascular effects explained.
What this means if you take stimulant medication
People taking ADHD stimulants who are considering microdosing psilocybin face a specific, named risk — not a vague theoretical concern — and should treat it accordingly.
Key points to carry into any conversation with a clinician:
- Psilocybin and stimulant medications both raise heart rate and blood pressure through independent but directionally overlapping mechanisms.
- The combination has not been studied in controlled trials for safety; the only published clinical data is a case report of harm, not a safety study.
- The risk is dose-dependent: a small microdose may produce less cardiovascular load than a moderate psilocybin dose, but there is no established "safe" threshold for the combination.
- If you are also taking any MAOI — whether prescribed (tranylcypromine, phenelzine, moclobemide) or used recreationally (Syrian rue, ayahuasca) — the combination is categorically contraindicated based on the documented case and known pharmacology.
- Stopping stimulant medication without medical guidance to enable microdosing is not a solution; stimulant discontinuation has its own risks and should be managed by a prescriber.
Before making any decision about microdosing alongside prescribed medication, complete our self-screener and bring the output of that conversation to a physician or prescriber who knows your cardiac history.
Practical harm reduction for those who proceed regardless
For completeness, harm-reduction frameworks — including guidance that applies to people who may proceed with microdosing despite these cautions — emphasise several steps that can reduce but cannot eliminate risk:
- Never combine with an MAOI under any circumstances when taking a stimulant medication.
- Start with the minimum possible dose of psilocybin and do not escalate on a day when a stimulant dose has been taken.
- Monitor cardiovascular parameters: know your baseline resting heart rate and blood pressure, ideally with a home cuff, before and after any session.
- Have a support person aware of the combination and knowing when to escalate to emergency services.
- Stop and seek immediate care if you experience severe headache, chest pain, palpitations, or marked blood pressure symptoms.
These steps reduce risk — they do not establish safety. No current evidence supports the combination as low-risk, and this article does not endorse it.
Further reading
- Microdosing Safety pillar hub — all safety topics in one place.
- Psilocybin and blood pressure medication interactions — antihypertensives and psilocybin.
- Psilocybin acute cardiovascular effects explained — the physiology in depth.
- Self-screening before microdosing checklist — a structured pre-decision tool.
Frequently asked
Is it safe to microdose psilocybin while taking Adderall or Vyvanse?
There are no controlled safety studies on this combination, and the only published clinical data is a 2024 case report of a hypertensive emergency in a patient combining psilocybin, Adderall, and an MAOI. Both substances raise blood pressure and heart rate through overlapping mechanisms. Combining them cannot be considered low-risk, and anyone taking stimulant medication should discuss this with a prescriber before making any decision.
Why is adding an MAOI to this combination especially dangerous?
MAOIs inhibit the enzyme that breaks down norepinephrine and dopamine. When an MAOI is present alongside a stimulant medication like amphetamine, catecholamine clearance is impaired and the stimulant's cardiovascular effects are dramatically amplified. Adding psilocybin to this pairing produces a three-way cardiovascular interaction documented in a published hypertensive emergency case report (J Psychoactive Drugs, 2024).
Does psilocybin actually raise blood pressure?
Yes. A pooled analysis of 14 clinical studies (536 sessions, Johns Hopkins, medRxiv 2026) found that psilocybin produces dose-dependent transient increases in systolic blood pressure and heart rate, most pronounced in the first two hours after ingestion. The authors note these are clinically meaningful in people with pre-existing cardiovascular vulnerability.
Should I stop my stimulant medication before microdosing?
No — stopping prescribed stimulant medication without medical guidance carries its own risks and is not a solution to the interaction concern. Any change to a prescribed medication must be managed by the prescribing clinician. Bring your microdosing interest to that clinician as part of a full medication review.
What are the warning signs that something is going wrong cardiovascularly?
Seek emergency care immediately if you experience a severe or sudden headache, chest pain or tightness, heart palpitations or a very rapid irregular heartbeat, shortness of breath, or vision changes during or after combining psilocybin with a stimulant medication. These can be signs of hypertensive emergency or cardiac arrhythmia.
References & sources
- Hypertensive Emergency Secondary to Combining Psilocybin, Dextroamphetamine-Amphetamine, and Tranylcypromine (J Psychoactive Drugs, 2024)
- Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies (Johns Hopkins, medRxiv 2026)
- Sarparast et al. — Psilocybin: A Clinician’s Guide to Pharmacological Interactions (Psychiatric Times)
- UCSF — Medical Contraindications to ‘Classic’ Psychedelic Use
This guide is general educational information about microdosing, not medical advice and not a recommendation to use any substance. It can’t account for your personal health. If you take medication or live with a mental-health condition, speak with a qualified professional before making any decision.
